Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01584986Phase 2Completed

Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease

Role: collaborator

NCT00416663Phase 1Unknown

Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure

Role: lead

NCT00523224Phase 1Unknown

ACPs Combined With CABG in Patients With CHF

Role: lead

NCT00523731Phase 1Completed

ACPs in Severe PAD/CLI by Direct Intramuscular Injection

Role: lead

NCT00384514Phase 2Unknown

EPC by Intracoronary Injection in Patients With Chronic Stable Angina

Role: lead

All 5 trials loaded